Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial
Rheumatology International · 2024
DOI: 10.1007/s00296-024-05665-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Rheumatology International, 2024. Verfasst von Line Uhrenholt und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark. l.uhrenholt@rn.dk. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Arthritis, Psoriatic, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Danish Regions Medicine Grants, Gigtforeningen, Manufacturer Vilhelm Pedersen and Wife's Grant after recommendation from The Novo Nordisk Foundation.
Abstract (Originalsprache)
To evaluate tumour necrosis factor inhibitor (TNFi) drug-levels and presence of anti-drug antibodies (ADAb) in patients with inflammatory arthritis who taper TNFi compared to TNFi continuation. Patients with rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis on stable TNFi dose and in low disease activity ≥ 12 months were randomised (2:1) to disease activity-guided tapering or control. Blood samples at baseline, 12- and 18-months were evaluated for TNFi drug-levels and ADAb. In total, 129 patients were randomised to tapering (n = 88) or control (n = 41). Between baseline and month 18, a significant shift in TNFi drug-levels were observed in the tapering group resulting in fewer patients with high drug-levels (change: − 14% [95% CI − 27 to − 1%]) and more with low drug-levels (change: 18% [95% CI 5–31%]). Disease activity was equivalent between groups at 18 months, mean difference: RA − 0.06 (95% CI − 0.44 to 0.33), PsA 0.03 (95% CI − 0.36 to 0.42), and axSpA 0.16 (− 0.17 to 0.49), equivalence margins ± 0.5 disease activity points. ADAb were detected in eight patients, all from the tapering group. TNFi drug-level category or ADAb were not predictive for achieving successful tapering at 18 months. TNFi drug-levels decreased during tapering which indicate adherence to the tapering algorithm. Despite the difference in TNFi drug-levels at 18 months, disease activity remained equivalent, and only few tapering patients had detectable ADAb. These data do not support using TNFi drug-level and/or ADAb to guide the tapering decision but future research with larger trials is needed. Trial registration: EudraCT: 2017-001970-41, December 21, 2017.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark. l.uhrenholt@rn.dk.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. l.uhrenholt@rn.dk.
- Section for Biostatistics and Evidence-Based Research, The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark. l.uhrenholt@rn.dk.
- Center of Rheumatic Research Aalborg (CERRA), Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.
ORCID-Profile: Line Uhrenholt, Karen B Lauridsen, Kirsten Duch, Lene Dreyer, Robin Christensen, Ellen-Margrethe Hauge, Anne Gitte Loft, Hans Christian Horn, Peter C Taylor, Kaspar R Nielsen, Salome Kristensen
Förderung
- The Danish Regions Medicine Grants
- Gigtforeningen
- Manufacturer Vilhelm Pedersen and Wife's Grant after recommendation from The Novo Nordisk Foundation
- Aase og Ejnar Danielsens Fond
- The Health Science Research Fund of the North Denmark Region
- Oak Foundation
- Manufacturer Vilhelm Pedersen and Wife’s Grant after recommendation from The Novo Nordisk Foundation
- The Department of Rheumatology at Aalborg University Hospital
Zitieren
APA
Uhrenholt, L., Sørensen, M. E. R., Lauridsen, K. B., Duch, K., Dreyer, L., Christensen, R., Hauge, E. M., Loft, A. G., Rasch, M. N. B., Horn, H. C., Taylor, P. C., Nielsen, K. R., & Kristensen, S. (2024). Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial. Rheumatology International. https://doi.org/10.1007/s00296-024-05665-7
Vancouver
Uhrenholt L, Sørensen MER, Lauridsen KB, Duch K, Dreyer L, Christensen R, et al. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial. Rheumatology International. 2024. doi:10.1007/s00296-024-05665-7
BibTeX
@article{Uhrenholt2024,
author = {Uhrenholt, Line and Sørensen, Mads E R and Lauridsen, Karen B and Duch, Kirsten and Dreyer, Lene and Christensen, Robin and Hauge, Ellen-Margrethe and Loft, Anne Gitte and Rasch, Mads N B and Horn, Hans Christian and Taylor, Peter C and Nielsen, Kaspar R and Kristensen, Salome},
title = {Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-024-05665-7}
}
EUVIMED